ASCO 2015 Highlights

RTOG 0522: The KRAS Variant and Response to Cetuximab

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

In many cancers, KRAS mutations can predict cancer risk, unique cancer biology, and response to certain therapeutic agents. RTOG 0522 was a phase 3 trial of cisplatin/radiation ± cetuximab for patients with locally advanced SCCHN, evaluating whether KRAS mutation status would predict the response to cetuximab in these patients (Weidhaas JB, et al. ASCO 2014. Abstract 6000).

Adjuvant Lapatinib Plus Chemoradiation in High-Risk Patients with SCCHN

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Maintenance Strategies in mCRC After First-Line Therapy

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Final Results of the CAIRO3 Study

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Prognostic Impact of Deficient Mismatch Repair in CRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Preoperative Chemoradiotherapy and Postoperative Chemotherapy in Locally Advanced Rectal Cancer—Results of the CAO/ARO/AIO-04 Trial

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

RAS Mutation Status and FOLFOX +/- Cetuximab—The OPUS Study

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Pidilizumab in Relapsed Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Page 226 of 330